GlassScriptPhysician profile
Robert O Flores
NPI 1932162013
$19,110.23
in general payments reported to CMS, 2019-2025
54 companies · $2,817 in 2025
The $2,817 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,648 · 2020: $2,777 · 2021: $3,433 · 2022: $2,126 · 2023: $2,507 · 2024: $2,803 · 2025: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,100 · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,099.78 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,194.78 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,121.91 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,663.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Radius Health, INC. | $1,241.87 | 2019-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,139.24 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Amgen INC. | $1,123.33 | 2019-2025 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $912.42 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $900.76 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $866.59 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $654.34 | 2019-2025 | Trintellix |
| Novartis Pharmaceuticals Corporation | $651.17 | 2019-2025 | |
| Amarin Pharma, INC. | $591.53 | 2019-2023 | |
| Pfizer INC. | $557.29 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $507.01 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Esperion Therapeutics, INC. | $374.26 | 2020-2025 | Nexletol |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.